NCT07163728 Leptin: A Marker for AML Chemo-Sensitivity
| NCT ID | NCT07163728 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fujian Medical University Union Hospital |
| Condition | AML |
| Study Type | OBSERVATIONAL |
| Enrollment | 86 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 86 participants in total. It began in 2025-08-01 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute Myeloid Leukemia (AML) is a malignant clonal disorder of hematopoietic stem/progenitor cells, with a five-year survival rate of approximately 30%. Chemotherapy resistance and relapse remain major challenges. Increased bone marrow adipocytes contribute to AML cell drug resistance.This study found that elevated levels of the adipokine leptin enhance oxidative phosphorylation (OXPHOS) in AML cells, accompanied by increased mitochondrial reactive oxygen species (mtROS), which stimulates antioxidant capacity and thereby induces chemotherapy resistance. By establishing a correlation between leptin levels in bone marrow supernatant and clinical outcomes in AML patients, this research provides novel strategic insights for targeting drug resistance and improving prognostic evaluation.
Eligibility Criteria
Inclusion Criteria: 1. Clinical diagnosis aligns with the "Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)"; 2. All patients are experiencing their first onset of the disease and have not received any related chemotherapy prior to the study; 3. Patients participate in the study accompanied by family members and sign informed consent documents. Exclusion Criteria: 1. Patients with concurrent malignancies requiring treatment; 2. Presence of infectious diseases, including SARS, viral hepatitis, or HIV/ AIDS; 3. Major surgery performed within the last 21 days; 4. Performance Status (PS) score \>3; 5. Severe liver or kidney dysfunction or serious infection; 6. Severe psychiatric conditions that impair understanding of the study protocol or voluntary withdrawal.
Contact & Investigator
Huifang Huang
STUDY DIRECTOR
Fujian Medical University Union Hospital
Frequently Asked Questions
Who can join the NCT07163728 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying AML. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07163728 currently recruiting?
Yes, NCT07163728 is actively recruiting participants. Contact the research team at huanghuif@fjmu.edu.cn for enrollment information.
Where is the NCT07163728 trial being conducted?
This trial is being conducted at Fuzhou, China.
Who is sponsoring the NCT07163728 clinical trial?
NCT07163728 is sponsored by Fujian Medical University Union Hospital. The principal investigator is Huifang Huang at Fujian Medical University Union Hospital. The trial plans to enroll 86 participants.